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Abstract
Production of nitric oxide by the inducible NO synthase
(iNOS) is known to be enhanced in chronic joint inflam-
mation and osteoarthritis as well as aseptic loosening of
joint prostheses. Initial studies yielded promising results
after inhibition of the nitric oxide synthase (NOS). How-
ever, the effect of NOS inhibition has not been studied at
the site of the primary function of NO, the microcircula-
tion of the synovium in vivo. Using our recently devel-
oped model for the in vivo study of synovial microcircu-
lation in the mouse knee joint, the effects of selective ver-
sus nonselective inhibition of iNOS were investigated by
means of intravital fluorescence microscopy. After resec-
tion of the patella tendon, the synovial fatty tissue was
exposed for intravital microscopy. Diameter of arteri-
oles, functional capillary density (FCD), diameter of ven-
ules, venular red blood cell velocity and leukocyte-endo-
thelial cell interaction were quantitatively analyzed be-
fore, and 10 and 60 min after intravenous injection of
NOS inhibitors [selective iNOS inhibitor N-iminoethyl-L-
lysine (L-NIL), and nonselective NOS inhibitor NG-nitro-
L-arginine methyl ester (L-NAME)]. Our results demon-
strate that L-NAME causes a significant decrease in the
arteriolar diameter and FCD associated with an increase
in the leukocyte accumulation in the synovium in vivo. In
contrast, L-NIL neither altered the microhemodynamics
nor the leukocyte-endothelial cell interaction in the syno-
vium, indicating its potential use for selective inhibition
of iNOS in joint inflammation. Using our method, further
studies will provide new insights into the unknown effect
of NOS inhibition on the synovial microvasculature in
inflammatory joint disease in vivo.
Copyright © 1999 S. Karger AG, Basel
Introduction
Many inflammatory diseases including chronic joint
inflammation are associated with an enhanced produc-
tion of nitric oxide. A variety of different types of cells are
able to synthesize NO from arginine in a reaction cata-
lyzed by NO synthase (NOS). This enzyme exists in the
form of several isoenzymes, the major distinction being
between inducible (iNOS) and constitutive forms (cNOS).
Cells which contain cNOS synthetize rapidly, but tran-
siently, small amounts of NO. In contrast, cells expressing
iNOS synthetize large amounts of NO for an extended
period following a delay of several hours during which the
enzyme is induced.
The findings that articular chondrocytes release large
amounts of NO by iNOS after incubation with proinflam-
matory cytokines or endotoxin and that also cells of the
synovium synthetize NO via iNOS in the arthritic joint
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provided the first evidence that NO may be involved in
the pathogenesis of joint disease [1, 2]. Subsequent animal
studies confirmed these observations by showing that
chondrocytes and synovial fibroblasts as well as extrava-
sated neutrophils and macrophages express iNOS in
chronic inflammatory joint diseases [2, 3]. In patients
with joint inflammation, induction of iNOS was demon-
strated in neutrophils, synovial fibroblasts, and chondro-
cytes [4, 5]. Furthermore, NO production has been shown
to be involved in osteoarthritis, ligament healing, and
aseptic loosening of endoprostheses [6]. These and other
findings envisage a potential use of therapeutic inhibition
of NO synthesis in joint inflammation. Nevertheless, the
impact of the enhanced NO release by iNOS in inflamma-
tion on the course of the disease has been discussed con-
troversially. Studies with the use of nonselective NOS
inhibitors showed an improvement in liver detoxification
in rats with inflammatory liver dysfunction [7], as well as
a suppression of arthritis in rats [8]. Investigations using
selective iNOS inhibitors in experimental arthritis re-
ported contradictory results [9, 10]. Furthermore, there
are several studies suggesting even beneficial effects of
selective iNOS inhibition in chronic joint inflammation
[6, 2, 10]. On the other hand, serious side effects of nonsel-
ective NOS inhibition on macro- and microhemodynam-
ics have been reported [11]. Recently, it has been shown
that inhibition of NO synthesis with NG-nitro-L-arginine
methyl ester (L-NAME) resulted in an enhanced leuko-
cyte-endothelial cell interaction and in alterations of the
endothelial cytoskeleton with subsequent albumin leak-
age from mesenteric postcapillary venules [12–14]. Inter-
estingly, in single perfused frog mesenteric venular vessels
nonselective inhibition of NOS led to a decrease in micro-
vessel permeability [15, 16]. However, some authors pos-
tulated that iNOS prevents leukocyte adherence in intesti-
nal inflammation and endotoxemia [17, 18].
Most of the investigations regarding NOS inhibition
and its effects on the microcirculation have used the rat
mesenterium. Yet, no studies have been reported which
directly demonstrate the in vivo effects of selective versus
nonselective NOS inhibitors at the site of the synovial
microcirculation. Therefore, it was our aim to investigate
the in vivo changes of the synovial microcirculation and
the leukocyte-endothelial cell interactions in the mouse
knee joint after selective, N-iminoethyl-L-lysine (L-NIL)
[19], versus nonselective NO synthase inhibition (L-
NAME), using our recently developed model for intravi-
tal microscopic analysis of the mouse synovial microvas-
culature [20].
Materials and Methods
Microsurgical Procedure
Female Balb/c mice (Charles River, Sulzfeld, Germany), weigh-
ing 18–21 g, were used for the experiments. The animals were kept in
an air-conditioned environment with 12-hour light/dark cycles,
housed in polystyrene cages and fed laboratory chow, supplemented
with 120 mg of vitamin E and 18,000 IU of vitamin A per kilogram
body weight (ssniff, Spezialdiäten, Soest, Germany), and water ad
libitum. Anesthesia was performed by inhalation of isoflurane 1.2%
(Forene, Abbott, Wiesbaden, Germany) and a combination of O2/
N2O. The mean arterial blood pressure was assessed by an arterial
catheter that was inserted into the tail artery and connected to a pres-
sure transducer (Sirecust 300 D, Siemens, Erlangen, Germany). The
microsurgical procedure was performed as described previously [20].
Animals were kept on a heating pad to stabilize body temperature
which was controlled by a rectal probe. The left limb was placed on a
stage with a slight flexion of the knee joint. Immobilization of the
extremity was achieved by fixation in silicone (Classic M, Munich,
Germany). After a 1-cm incision was made distally of the patella ten-
don, partial skin resection ensued. The patella tendon was carefully
mobilized and partially resected. Afterwards, the ‘Hoffa’s fatty body’
(intra-articular synovial tissue of the knee joint) was visualized with-
out the need of opening the joint capsule. After superfusion with 5 ml
of sterile saline, a cover glass was placed on the knee capsule, and the
intravital microscope was directed on the synovium. Special care had
to be taken to avoid any constraint of the preparation. After intravi-
tal microscopy, the animals were sacrificed with 10 mg of pentobar-
bital (Nembutal; Sanofi, Hannover, Germany) intravenously.
Experimental Protocol
The animals were allocated into three groups. The control group
received a bolus injection of 0.1 ml sterile saline (n = 11) through a
venous catheter. In two other groups, either the nonselective NOS
inhibitor L-NAME (5 mg/animal, n = 7) or the selective iNOS inhibi-
tor NIL (2 mg/animal, n = 7) was administered intravenously as a
bolus immediately after the preparation. The dose of L-NIL has been
chosen according to results of pilot studies in 3 mice with an inflamed
knee joint. In these experiments, 2 mg of L-NIL given as a bolus
intravenously were found to completely abolish elevated plasma
nitrite/nitrate concentrations to almost control levels. Intravital mi-
croscopy was performed in all animals prior to as well as 10 and
60 min after the administration of the inhibitors.
Intravital Fluorescence Microscopy
The microscopic setup has been described in detail previously
[21]. A 20-fold water immersion objective (Zeiss Axiotech vario 100
HD microscope, Acroplan 20!/0.5 W, Zeiss, Oberkochen, Germa-
ny) was used to observe the synovial microvasculature under epi-
illumination. The images were recorded with a video camera (FK
6990 IQ-S, Piper, Schwerte, Germany) onto S-VHS video tapes
(Sony, Köln, Germany) for later off-line analysis. Epi-illumination
was achieved with either a 12-volt, 100-watt halogen lamp, or a 100-
watt HBO mercury vapor lamp (Zeiss), depending on the fluorescent
marker. The halogen lamp was used in conjunction with the Zeiss
filter set 09 (BP 450-490, FT 510, LP 520) for measurements involv-
ing fluorescein isothiocyanate-labeled dextran (FITC-dextran). The
HBO lamp and the Zeiss filter set 15 (BP 450-490, FT 546/12, FT
580, LP 590) were used for measurements involving rhodamine 6G.
Two to three regions of interest per animal were measured, contain-
MAP, mm Hg
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Table 1. Macro- and microhemodynamic parameters
Parameter Control (n = 11)
baseline 10 min 60 min
L-NAME (n = 7)
baseline 10 min 60 min
L-NIL (n = 7)
baselline 10 min 60 min
78B7 84B7 85B8 80B7 89B13 87B10 80B7 84B8 82B5
Arteriole diameter, Ìm 11.1B1.0 11.7B1.2 11.1B1.1 10.5B0.8 7.6B0.8* 9.9B0.5 11.7B0.8 12.1B0.9 11.8B1.2
FCD, cm/cm2 227B15 242B13 207B19 228B15 151B19* 149B17* 227B13 241B10 238B11
Venule diameter, Ìm 22.3B2 23.7B1.9 23.5B2.3 26.1B3.6 22.4B4.0 22.3B5.1 30.6B5.4 27.3B4.2 28.4B4.6
Venular RBC velocity, mm/s 1.2B0.2 1.3B0.1 1.3B0.1 1.7B0.2 1.1B0.2* 1.4B0.4 1.7B0.4 1.6B0.3 1.7B0.4
MAP = Mean arterial pressure. Diameter, FCD, and venular RBC velocity were assessed by computer-assisted image analysis. Data are
given as means B SEM. p values calculated by Friedman’s test and Dunn’s follow-up testing. p values !0.05 were considered significant. * p !
0.05 vs. baseline.
ing one to three postcapillary venules (18–40 Ìm in diameter) or arte-
rioles (8–14 Ìm in diameter), as well as capillaries. By means of a
computer-controlled stepping-motor-driven platform, identical vessel
segments were reinvestigated with respect to the above-described
parameters. For visualization of leukocytes, the fluorescent marker
rhodamine 6G (Sigma) was injected intravenously as a single bolus of
0.15 mg/kg body weight immediately prior to each measurement. For
labeling of the plasma, injection of the in vivo fluorescent plasma
marker FITC-dextran (molecular mass 150 kD; 15 mg/kg body weight
i.v.; Sigma, Oberhaching, Germany) was performed. The double-fluo-
rescence technique allowed for subsequent investigation of vessel
diameter, venular RBC velocity, functional capillary density (FCD),
leukocyte-endothelial cell interaction, and macromolecular extravasa-
tion in identical vessel segments. Data analysis was performed off-line
using a computer-assisted microcirculation analysis system (CAP-
Image/CAMAS, Dr. Zeintl, Heidelberg, Germany) [22].
Microcirculatory Analysis
The following microvasculatory parameters were assessed using
intravital microscopy: FCD, diameter of arterioles and venules, and
venular RBC velocity. Furthermore, leukocyte-endothelial cell inter-
actions were determined by measuring the fraction of rolling leuko-
cytes and the number of leukocytes adherent to the endothelium.
FCD was assessed by image analysis (CAMS) as the length of RBC-
perfused capillaries per observation area (given as cm/cm2). Rolling
leukocytes were defined as cells which were rolling along the vessel
visibly slower than the main bloodstream and loosely interacting
with the endothelium. Differences in vessel diameter, blood flow
velocity, and total number of leukocytes were corrected by examining
the rolling fraction, given as the number of rolling leukocytes to the
sum of rolling and all passing leukocytes through a defined vessel
segment. Adherent leukocytes were defined as cells which remained
attached to the endothelium for the entire 30-second observation
period. Data are expressed as cells per square millimeter endothelial
surface, which was calculated from the diameter and the length of the
vessel segment (200 Ìm).
Statistical Analysis
The data are expressed as means B SEM. Statistical significance
was determined using repeated measurement ANOVA on ranks
(Friedman’s test) and Dunn’s follow-up testing. p values !0.05 were
considered significant.
Results
Mean arterial blood pressure was not altered in any of
the groups during the entire observation period (table 1). In
the control group, there was no significant change in the
microvascular parameters, as shown in table 1. In contrast,
10 min after injection of L-NAME the diameter of arteri-
oles significantly decreased from 10.5 B 0.8 to 7.6 B
0.8 Ìm and remained decreased (9.9 B 0.5 Ìm) 60 min
after injection. In the same group, the FCD was reduced
from 228 B 15 to 151 B 19 cm/cm2 at 10 min and to 149 B
17 cm/cm2 60 min after injection. Furthermore, RBC
velocity in postcapillary venules was reduced 10 min after
injection of L-NAME from 1.75 B 0.21 to 1.05 B 0.24
mm/s. The fraction of rolling leukocytes and the number of
cells adherent to the endothelium were increased 10 min
after L-NAME injection from 0.20 B 0.03 to 0.47 B 0.07
and from 81 B 14 to 236 B 41 mm–2, respectively (fig. 1,
2). The number of adherent leukocytes remained elevated
until 60 min after L-NAME injection (361 B 105 mm–2;
fig. 2). Figure 3 shows two pictures of postcapillary venules
of the synovium prior to the administration of L-NAME
and 10 min after L-NAME injection, where large accumu-
lation of leukocytes is visible. Furthermore, there was no
significant change in the diameter of postcapillary venules
in all groups (table 1). In contrast to the L-NAME group, no
significant changes in the microvascular parameters were
observed in the animals after L-NIL administration (ta-
ble 1, fig. 1, 2).
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Fig. 1. Fraction of rolling leukocytes in postcapillary venules in the
synovium of the mouse knee joint prior (baseline), and 10 and
60 min after intravenous injection of L-NAME and L-NIL. Data are
given as means B SEM. * p ! 0.05 vs. baseline.
Fig. 2. Number of leukocytes adherent to the endothelium in post-
capillary venules in the synovium of the mouse knee joint prior (base-
line), and 10 and 60 min after intravenous injection of L-NAME and
L-NIL. Data are given as means B SEM. * p ! 0.05 vs. baseline.
Fig. 3. Leukocyte-endothelial cell interaction in a postcapillary venule of synovial fat tissue visualized by intravital
fluorescence microscopy after in vivo staining of leukocytes with rhodamine 6G (!307, bars = 50 Ìm, arrows indi-
cate leukocyte examples). A Prior to the administration of L-NAME only a few leukocytes can be seen. B Distinct
accumulation of leukocytes occur 10 min after L-NAME injection.
BA
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Discussion
The crucial role of iNOS-mediated NO production in
chronic joint disease has been addressed by several stud-
ies, but it remained unclear whether this NO release is
harmful or protective. Nonselective blocking of NOS has
been shown to suppress the development of experimental
arthritis in rats [8], although the therapeutic administra-
tion of both selective and nonselective iNOS inhibitors
yielded contradictory results [9, 10]. Moreover, little is
known about the effects of NOS inhibition on the synovial
microvasculature in vivo. Therefore, the aim of our study
was to analyze the effects of selective versus nonselective
inhibition of iNOS on the synovial microcirculation in
vivo.
For this study, our recently described approach to the
mouse knee joint using intravital microscopy of the syno-
vial tissue was used [20]. The preparation for the quanti-
tative analysis of the synovial microcirculation has been
shown to be stable for at least 60 min. The synovial tissue
observed by this method is composed of the synovial cell
layer, which is a thin cell layer, and the subsynovium.
Within this tissue arterioles, capillaries, and venules can
be analyzed quantitatively.
However, in studies investigating the effects of NOS
inhibitors on the microcirculation in vivo, the mesentery
but not the synovium was used [14, 18, 23]. In compari-
sion to other soft tissues, the synovial microvasculature
presents with a dense capillary network, a high RBC
velocity, and a dense fenestration of the endothelium [20].
This difference in the microvasculature is presumably
dud to the requirement of the synovium to nourish the
avascular cartilage.
Our results demonstrate that inhibition of both NOS
isoforms (cNOS and iNOS) by L-NAME has crucial
effects on the synovial microcirculation. The increase in
the fraction of rolling leukocytes 10 min after injection is
in accordance with a study of Davenpeck et al. [13]. They
observed a dose-dependent increase in leukocyte rolling
after administration of L-NAME in the rat mesentery. It
was suggested that this effect was most probably due to
the presentation of P-selectin on endothelial cells and
platelets after inhibition of NO production. P-selectin is
an adhesion molecule that promotes leukocyte rolling and
platelet adhesion. Nevertheless, after administration of
NO donors, Kubes et al. [23] found that NO prevented
leukocyte adhesion in ischemia-reperfusion of the rat
mesentery, but failed to affect P-selectin-mediated leuko-
cyte rolling. In another study, a significant enhancement
of leukocyte adherence to the endothelium was observed
in postcapillary venules in the rat mesentery after L-
NAME superfusion, which is in accordance with our
results of an enhanced leukocyte accumulation in the
synovium 10 and 60 min after L-NAME injection [14].
Several mechanisms may explain these results. Decrease
in NO production results in a reduction of cGMP in endo-
thelial cells, which leads to contraction of these cells and
subsequent expansion of the junctions between adjacent
endothelial cells, and platelet-leukocyte aggregation.
Another effect of an attenuated NO release is the expres-
sion of adhesion molecules, such as CD11/CD18, VCAM-
1, and ICAM-1 [14, 24]. The mechanisms of L-NAME-
induced adhesion are still under debate. Recent studies
have shown that NO can inhibit NF-ÎB activation and
subsequent VCAM-1, ICAM-1, and E-selectin expression
by increasing the expression and nuclear translocation of
IÎB-· [25, 26]. Finally, all these mechanisms may pro-
mote leukocyte adherence and subsequent emigration
through the endothelium [14]. Another effect of L-NAME
on the synovial microcirculation was a significant de-
crease in the arteriolar diameter and the FCD 10 and
60 min after administration. This is most likely due to
inhibition of cNOS and subsequent arteriolar constric-
tion, leading to a reduced perfusion of the synovial tissue.
Further support of this explanation is the decrease in the
RBC velocity in postcapillary venules throughout the
entire observation period which was significant 10 min
after L-NAME administration. In a recent study, local L-
NAME administration was found to reduced blood flow
and enhance leukocyte adhesion via the expression of
CD11/CD18 and its ligand ICAM-1 on the endothelium
in rat skeletal muscle [24]. Furthermore, it has been
shown by means of laser Doppler flowmetry that basal
joint blood flow and vascular resistance were significantly
reduced after L-NAME administration in the rabbit knee
joint [27].
After selective iNOS inhibition with L-NIL, which has
been shown to be a potent suppressor of iNOS in vitro and
in vivo [19], we did not detect any significant alterations
in the synovial microhemodynamics or leukocyte-endo-
thelial cell interactions indicating that L-NIL does not
inhibit cNOS. This would be the assumption for the thera-
peutic use of an iNOS inhibitor, which is suggested to be
sufficient in experimental arthritis by a number of studies
[3, 6, 10]. One supposed mechanism is that L-NIL sup-
presses intra-articular NO synthesis by the synovium and
the cartilage, and thus protects the joint possible inflam-
matory and erosive effects of prolonged, excessive local
production of NO. Another possibility is that iNOS inhib-
itors function as immunomodulators which downregulate
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the immune responses underlying the development of
chronic joint inflammation [10].
In summary, we have shown that administration of L-
NAME leads to a decreased perfusion in the synovium as
well as to an increased leukocyte adhesion. In contrast,
L-NIL does neither alter the microhemodynamics nor the
leukocyte-endothelial cell interaction in the mouse syno-
vium significantly, indicating its potential use for thera-
peutic selective inhibition of iNOS in joint inflammation.
Further investigations are necessary to evaluate whether
selective iNOS inhibition has the potential to ameliorate
acute and chronic joint diseases or whether it enhances
the inflammatory reaction due to an enforced leukocyte
adherence and emigration into synovial tissue. Such stud-
ies could help to understand the significance of the
enhanced NO production in orthopedic disease such as
chronic joint inflammation and aseptic loosening of joint
prostheses.
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